london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal


Efficacy of intravitreal ranibizumab injection for treatment of diabetic macular edema

Poster Details

First Author: H.Sımsek TURKEY

Co Author(s):    G. Kaya   Y. Yılmaz               0   0 0   0 0   0 0   0 0

Abstract Details


To evaluate the functional and anatomical results after intravitreal ranibizumab injection in patients with diabetic macular edema unresponsive to previous laser photocoagulation.


Dunya Eye Hospital ,Department of Ophthalmologyi,Istanbul, Turkey


Seventy eyes of fity patients with diffuse diabetic macular edema that had failed to respond previous laser photocoagulation were treated with intravitreal ranibizumab injections (0.5 mg/0.05ml) and enrolled in the study. These patients were evaluated with logMAR best correcred visual acuity (BCVA), biomicroscopy , intraocular pressure and optical cohorence tomograhy (OCT) before first injection, and at 1st, 3rd, 6 th month and last visit.


Seventy eyes of fity patients of 50 patients with a mean age of 54.60±6,85 years (42-69) were included in the study. Mean follow-up was 14.3 months (6-30 months) and mean number of injections during this period was 3.6. The mean logMAR BCVA was 0.75±0.5 before the injections , it was improved to 0.67±0.4, 0.64±0.4, 0.60±0.4 and 0.61±0.4 at 1-month , 3-month and last visit respectively. There was a statistically significant visual acuity improvement at all visits except 1-month (p<0.05 , Friedman test). There was a central foveal thickness reduction at all visits after the injection but it was statistically significant at 6-month and last visit (p<0.05, Wilcoxon test ). we didn't observe any complication due to the procedure.


In the short term, macular edema decreased and visual acuity increased in the vast majority of patients after intravitreal injection of ranibizumab. However, long term studies are needed to show permanency of this anatomical and functional recovery.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy